Opening book details…
Can I read IDH mutations in older patients with diffuse astrocytic gliomas on EtoBox?
IDH mutations in older patients with diffuse astrocytic gliomas by Andrews, Cyril; Prayson, Richard A. is a Medicine article available to read on EtoBox.
What is IDH mutations in older patients with diffuse astrocytic gliomas about?
In 2016, the World Health Organization recommended that isocitrate dehydrogenase (IDH) mutation status be included in the classification of diffuse astrocytic gliomas. IDH mutations are part of the current definition of oligodendrogliomas and are predictive of a better outcome in diffuse astrocytic gliomas. A few studies, examining the role of routine IDH testing in older patients, came to differing conclusions and made differing recommendations regarding a routine IDH testing algorithm with respect to patient age. The purpose of this study was to examine IDH mutations in a series of diffuse astrocytic gliomas [N = 381; 53 diffuse astrocytomas (WHO grade II), 66 anaplastic astrocytomas (WHO grade III) and 262 glioblastomas (WHO grade IV)], paying particular attention to age of patient and any relationship between age and IDH status. IDH status was evaluated by immunohistochemistry with IDH-1 (R132H) antibody and if negative staining was noted, followup polymerase chain reaction (PCR) testing assessing for IDH-1 and IDH-2 mutations was performed. Overall, IDH mutations were discovered in 50.1% of grade II tumors, 54.4% of grade III tumors and 15.1% of grade IV tumors. Of tumors stud
Who reads IDH mutations in older patients with diffuse astrocytic gliomas?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Andrews, Cyril; Prayson, Richard A.
- Publisher
- Elsevier Science; Elsevier ; W. B. Saunders Co., Ltd.; Elsevier BV (ISSN 1532-8198)
- Published
- 2020
- Language
- EN
- Field
- Medicine (Health Sciences)